Experience
Adaptive Phage Therapeutics Enters Into Definitive Merger Agreement With BiomX
March 6, 2024
Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.
Related contacts
Jackpocket Reaches Agreement to Be Acquired by DraftKings for $750 Million
February 15, 2024
Cooley advised Jackpocket, the first licensed third-party lottery courier app in the US, on its definitive agreement to be acquired by DraftKings for $750 million.
Related contacts
Related Practices & Industries
CallTower Receives Investment From BV Investment Partners
November 16, 2023
Cooley advised CallTower, an international leader in delivering cloud-based, enterprise-class communications, contact center and collaboration solutions, on its investment from BV Investment Partners.
Related contacts
Related Practices & Industries
Veritone Acquires Broadbean
June 5, 2023
Cooley is advising Veritone, an artificial intelligence company, on its acquisition of Broadbean for $52 million.
Related contacts
Related Practices & Industries
Immatics Enters Global Exclusive License Agreement With Bristol Myers Squibb
December 22, 2021
Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its license, development and commercialization agreement with Bristol Myers Squibb for its TCR bispecific candidate, IMA401. Lawyers Ken Krisko, Carly Robinson, Brian Stalter and Stephanie Palmer led the Cooley team advising Immatics.